Risk factors for motor response complications in L-dopa-treated parkinsonian patients.
Peppe
A
A
Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892.
Dambrosia
J M
JM
Chase
T N
TN
D000328:Adult; D000367:Age Factors; D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002230:Carbidopa / Q000009:adverse effects* / Q000627:therapeutic use; D004338:Drug Combinations; D004409:Dyskinesia, Drug-Induced / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007980:Levodopa / Q000009:adverse effects* / Q000627:therapeutic use; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D009043:Motor Activity / Q000187:drug effects*; D009460:Neurologic Examination / Q000187:drug effects*; D010300:Parkinson Disease / Q000188:drug therapy*; D012307:Risk Factors
D000978:Antiparkinson Agents; D004338:Drug Combinations; C009265:carbidopa, levodopa drug combination; D007980:Levodopa; D002230:Carbidopa